Life Science Intelligence

The first human implantation of Paradromics ’ BCI marks more than another milestone in brain-computer interface development. It highlights a different vision for the field, one centered on restoring communication rather than controlling a cursor or robotic arms. On June 17th, surgeons at the University of Michigan Health implanted Paradromics’ Connexus device into the cortex of a woman living with motor neuron disease as part of the company’s Connect-One early feasibility study. The patient will be followed for six years under an FDA investigational device exemption that Paradromics says was the first IDE for speech restoration with a fully implantable BCI. While many companies have focused on motor control, Paradromics is pursuing one of neurology’s most significant unmet needs: helping patients regain their ability to communicate. Why Paradromics’ BCI Is Targeting Speech The potential patient population extends well beyond a single neurological condition. According to the World Healt...

There are few corners of medtech that capture the imagination quite like surgical robotics. It is one of the rare areas in medicine where technology visibly bends our perception of what is possible. It combines hardware, software, imaging, artificial intelligence, and human expertise into systems that would have sounded like science fiction only a generation ago. In a world where surgeons sit at a robotic console, navigate a catheter through the beating heart, or perform a procedure from hundreds of miles away, we are reminded that medicine is ultimately limited only by our ability to imagine a better way. That is why all of us at LSI, from Scott and me to the broader team, have always loved this market. A decade ago, I walked into Intuitive Surgical and truly fell in love with medtech. Over the years that followed, I had the privilege of working alongside many of the pioneers who helped create this category. I saw robotics from multiple vantage points: in research environments explori...

In Q2 2026, LSI Alumni companies raised $1.9 billion, up from $1.2 billion in Q1 , reflecting another active quarter for medtech funding. The quarter included 47 funding events and strategic transactions, ranging from early-stage venture financings to late-stage growth rounds, acquisitions, IPOs, and strategic partnerships. Highlights included six acquisitions, two IPOs, and three $100 million financing rounds, reflecting continued investor interest in companies reaching key clinical, regulatory, and commercial milestones. Investment activity spanned a wide range of sectors, including cardiovascular, neurotechnology, robotics, diagnostics, women’s health, and surgical innovation, offering a snapshot of where capital flowed across the medtech ecosystem during Q2. What’s Inside the Report The complete Q2 2026 LSI Alumni Funding Report includes every funding event and strategic transaction involving LSI Alumni companies during the quarter, including: 47 funding events and strategic transa...

Under the direction of Founder and CEO Dr. Hilla Ben-Pazi, Avertto Medical is developing what it describes as the world’s first continuous stroke monitoring and alert system. Inspired by Ben-Pazi’s experience addressing stroke patients as a neurologist, the company is working to identify cerebrovascular changes before irreversible neurological damage occurs. By continuously monitoring carotid artery pulse waveforms and applying algorithm-driven analysis, Avertto aims to give clinicians an earlier opportunity to recognize and respond to evolving stroke events, potentially transforming how one of medicine’s most time-sensitive conditions is managed. Origin Story For Ben-Pazi, Avertto’s origins began at the bedside. “The inspiration came directly from my work as a neurologist seeing individuals with irreversible disabilities,” Ben-Pazi explained. “It was frustrating to see the devastating consequences of delayed stroke recognition.” While stroke treatments have improved dramatically, she ...

Under the direction of Founder and CEO Dr. George Kramer, NeoCor is developing a novel transcatheter solution for mitral and tricuspid valve disease. Guided by the philosophy of “One Medicine, One Health, One World,” the company’s CoApt Valve™ is being designed for both human and canine patients, combining a leaflet augmentation approach with an ultra-low profile delivery system intended to expand access to minimally invasive treatment. As NeoCor advances toward first-in-human studies, the company is positioning its technology to address one of structural heart’s largest remaining unmet needs. Origin Story NeoCor was founded by Dr. George Kramer, who serves as the company’s Founder and CEO. From the beginning, the company’s vision has extended beyond a single patient population. “Adhering to the philosophy of ‘One Medicine, One Health, One World,’ the CoApt Valve is being developed for both canine and human mitral valve disease,” Kramer explained. “It is designed to provide a minimally...

On June 3rd, Medtronic revealed a pair of investments that caught the attention of the electrophysiology market. The companies are located on opposite sides of the world, but they share a common focus: intracardiac echocardiography (ICE) catheters. One investment went to California-based Beluga Medical. The other went to Shenzhen-based CardioACC. Financial terms were not disclosed, but the significance of the deals extends well beyond the size of the checks. Together, the investments offer insight into where Medtronic believes cardiac ablation is heading and how it plans to strengthen the Affera platform as competition intensifies across electrophysiology. Why Intracardiac Echocardiography Has Become a Strategic Priority Medtronic has been clear about its intentions. The company plans to integrate ICE capabilities into its Affera mapping and ablation ecosystem. Rebecca Seidel, president of Medtronic’s Cardiac Ablation Solutions business, described ICE catheters as a core component of m...

On June 2nd, Contraline announced a $92.5 million Series B financing. While the size of the round is notable, the more meaningful signal comes from who participated. The financing was co-led by BVF Partners and RA Capital Management, two crossover funds that almost exclusively back therapeutics. Their participation suggests they see more than an interesting technology. They see the potential for an entirely new market with a drug-sized outcome. Here’s what the numbers reveal. The Investment Case for Male Contraceptives The biggest opportunity starts with what is missing. For decades, men have effectively had only two contraceptive choices: condoms and vasectomy. No new male method has reached the market in a generation. That helps explain why today’s global male contraceptives market is valued at only about $1.12 billion. The category remains small largely because there are so few products available, not necessarily because demand is limited. Research suggests the market could look ver...

Every LSI event brings together dozens of companies developing new medical technologies, but a handful always leave a particularly strong impression. Following LSI Asia ‘26 in Singapore, LSI’s Market Intelligence team reviewed presentations from more than 70 companies to identify five medtech startups that stood out based on their technology, commercial potential, recent milestones, and the markets they are pursuing. One trend became immediately apparent. Many of this year’s most compelling innovators came from across the Asia-Pacific region, demonstrating that companies headquartered in Singapore, China, and Thailand are increasingly building technologies designed for global adoption rather than regional markets alone. Below are five companies that captured our attention and the market dynamics supporting each opportunity. Aqua Medical Aqua Medical is developing an endoscopic treatment designed to address type 2 diabetes through a minimally invasive procedure instead of lifelong dru...

Under the direction of CEO Rolee Kumar, Marine Biomedical is advancing a novel approach to bone regeneration by transforming mother of pearl from Western Australia’s pearling industry into a biomaterial designed to support natural bone healing. Built on research originating at the University of Western Australia, the company has developed PearlBone™, a marine-derived bone graft substitute that combines the consistency and scalability of manufactured materials with the biological architecture found in nature. With an FDA 510(k) submission under review, a planned clinical trial on the horizon, and manufacturing operations established in Broome, Marine Biomedical is working to bring an entirely new category of regenerative biomaterials to orthopedic surgeons. Origin Story Marine Biomedical’s roots can be traced back to the University of Western Australia and the work of regenerative medicine pioneer Professor Ming Hao Zheng, who recently received the Member of the Order of Australia for h...

Under the direction of Co-Founder and CEO Intan Oldakowska, PhD, Earflo has brought to market an FDA-cleared, at-home medical device designed to treat the negative middle ear pressure that leads to fluid buildup and chronic ear infections and avoid the path toward surgery. By transforming treatment into something as familiar as drinking from a sippy cup, Earflo aims to address one of the most common pediatric conditions with a solution that is non-invasive, child-friendly, and designed for use at home. Following FDA clearance and a U.S. commercial launch, the company is now focused on expanding access for families while building evidence that earlier intervention can improve quality of life for both children and parents and help avoid ear tube surgery. Origin Story Earflo traces its roots to the Stanford Biodesign program, where innovators are trained to identify significant unmet clinical needs before ever thinking about solutions. For Oldakowska and her future co-founders, that proce...

Under the direction of Founder and CEO Christoff Heunis, PhD, Flux Robotics is developing a magnetic vascular navigation platform designed to give physicians more controlled steering of guidewire movement inside blood vessels. By replacing the traditional reliance on pushing and twisting wires from outside the body with magnetically guided tip steering, the company aims to make one of the most challenging steps in vascular intervention more predictable, repeatable, and accessible. As vascular disease burdens rise worldwide and specialist shortages intensify, Flux is pursuing a new approach to minimally invasive surgery that could help more physicians successfully treat more patients. Origin Story For Heunis, the inspiration behind Flux Robotics traces back to a deeply personal experience. “When I was 20, studying mechatronic engineering in South Africa, my best friend Shaun called me,” he recalled. “I’ve known Shaun since I was five, and his mother was like family to me. She had suffer...

Under the direction of CEO Tyler Zanon, EndoShunt Medical is developing a minimally invasive endovascular shunting device designed to give trauma surgeons temporary, targeted control over abdominal blood flow while maintaining perfusion to the rest of the body. In the most severe hemorrhage cases, where every minute can shape both survival and long-term quality of life, EndoShunt is working to replace blunt tools with a more controlled approach. As Zanon put it, “EndoShunt gives trauma surgeons the gift of time, so they can give trauma patients the gift of life.” Origin Story For Zanon, the mission behind EndoShunt is closely tied to the realities of trauma care. Based in Chicago, he has spent roughly 15 years in healthcare product development, first in academia and then in industry. Living in a major city with high rates of traumatic injury, he has seen how urgent the problem remains. “We haven’t seen actual innovation since World War II,” Zanon said. He often explains the challenge w...

Over the past several weeks, acquisition announcements have arrived at a rapid pace across the industry. Between transactions involving Medtronic, ResMed, Artivion, and Roche, nearly $2 billion in deal value has been announced in a short period of time. The headlines naturally raise a question: are we witnessing a true surge in medtech M&A , or are a handful of high-profile deals creating that impression? A review of recent transactions, combined with activity tracked in Compass AI , suggests that strategic buyers remain highly active. However, the broader data indicate a market that is accelerating within an established trend rather than entering entirely new territory. The Same Acquisition Playbook Continues to Win Although the companies and technologies differ, the latest transactions share several common characteristics. Strategic acquirers continue to target businesses with commercial traction, attractive growth profiles, and technologies that strengthen existing franchises. R...

Siemens Healthineers sits among the largest companies in medtech. With approximately $25 billion in revenue in 2025, the company operates at a scale comparable to some of the industry’s biggest names and continues to invest heavily in markets where it sees long-term growth potential. A series of partnership announcements over the past year offers a window into where Siemens Healthineers appears to be investing for the future. Across robotics, AI, diagnostics software, and health system infrastructure, Siemens Healthineers has assembled a network of relationships that increasingly points toward one destination: neuro. Viewed individually, each agreement serves a specific purpose. Taken together, they suggest a broader strategy centered on neuroimaging, precision therapy, and integrated clinical workflows. A Company Becoming More Focused Siemens AG announced plans to deconsolidate its majority stake in Siemens Healthineers, a process that has been underway for some time. For Healthineers...

With Q2 already underway, the latest medtech Q1 earnings reports offer an early read on where major strategics are gaining momentum, where pressure is building, and what strategic priorities are becoming clearer. This quarter’s results point to a consistent theme: focused portfolios are outperforming broader platforms. Companies concentrated in clearly defined growth markets, particularly cardiovascular/structural heart, are delivering stronger execution. More diversified players remain highly competitive, but they are managing a wider mix of operational, integration, and macroeconomic challenges. A closer look at the numbers makes that trend difficult to ignore. Focused Players Continue to Separate Themselves Abbott delivered $5.5 billion in Q1 Medical Devices revenue, representing 8.5% organic growth and 13.2% reported growth year over year. Electrophysiology, Rhythm Management, and Heart Failure each posted double-digit gains, while the U.S. launch of Volt supported EP performance. ...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, secure funding, launch partnerships, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). Avatar Medical Received FDA 510(k) clearance for Avatar Medical Vision, its software platform for instant 3D medical image processing, review, and surgical planning, enabling commercialization in the U.S. This clearance also establishes compatibility with the Barco Eonis 3D glasses-free display, forming the foundation of Eonis Vision, a joint solution that aims to bring clinicians and patients together around a shared, real-time view of anatomy during consultations. Axoft Raised an oversubscribed $55M Series A led by C.P. Group Innovation, with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. The company will use the funds to expand global clinical trials, advance U.S. regu...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, launch partnerships, achieve clinical milestones, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). APEX Biologix Welcomed LSI Alumni Jeff Cambra to its Board of Directors. Cambra brings extensive experience across the medical device and therapeutics industry, with leadership roles spanning general management, sales, marketing, and product development, along with experience supporting commercialization strategy, portfolio management, and strategic transactions. Aqua Medical Announced 12-month follow-up clinical data outside the U.S. for its proprietary radiofrequency vapor ablation platform, highlighting the potential of its proximal intestinal mucosal ablation procedure as a durable treatment for type 2 diabetes. Results showed up to a 2.6% reduction in HbA1c, 100% elimination of exogenous insulin in treated patients, 80% rema...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). Adialante Granted its second U.S. patent covering the core technology behind its ability to image in MRIs using radio waves. The company is developing a new class of mobile MRI systems designed to deliver diagnostic-quality imaging directly to practices without the need for construction or major capital investment. Angelini Ventures Welcomed Samantha Wong, PhD, as Investment Analyst. Dr. Wong played a key role in the launch of EspressoLab by Angelini Ventures and the establishment of the company’s Singapore office. Apreo Health Announced the appointment of LSI Alumni David Amerson to its Board of Directors and a strategic investment from OSF Ventures, the corporate investment arm of OSF HealthCare. Amerson has over 30 years of leadership...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). Activ Surgical Partnered with Medical Dynamics to be the company’s exclusive distribution partner in Belgium, the Netherlands, and Luxembourg for ActivSight™. ActivSight Intelligent Light is the first and only modular form-factor with multimodal Advanced Visualization, allowing surgeons to augment their senses using augmented reality overlays. Adagio Medical Submitted PMA application to the FDA for its vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia in patients with ischemic or non-ischemic structural heart disease. The submission is supported by the FULCRUM-VT pivotal IDE trial, which enrolled 209 patients and demonstrated 97.4% acute clinical success, 84.3...